- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: Wechsler Preschool and Primary Scale of Intelligence.
Displaying page 1 of 1.
EudraCT Number: 2017-002803-81 | Sponsor Protocol Number: TREX | Start Date*: 2020-04-03 | |||||||||||
Sponsor Name:IRCCS ISTITUTO GIANNINA GASLINI | |||||||||||||
Full Title: Neurodevelopmental outcome after standard dose sevoflurane versus low-dose sevoflurane/dexmedetomidine/remifentanil anaesthesia in young children | |||||||||||||
Medical condition: Children under the age of 2 years having surgery lasting at least 2 hours | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003173-22 | Sponsor Protocol Number: BP30153 | Start Date*: 2020-11-12 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: A Phase II Multi-Center, Randomized, Double-Blind, 24-Week, Parallel Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Children and Adolescents Age... | ||
Medical condition: Autism Spectrum Disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-003556-31 | Sponsor Protocol Number: SHP-607-201 | Start Date*: 2015-02-10 |
Sponsor Name:Premacure AB, A Member of the Shire Group of Companies | ||
Full Title: Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care | ||
Medical condition: Retinopathy of Prematurity (ROP) | ||
Disease: | ||
Population Age: Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PL (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-005571-39 | Sponsor Protocol Number: 4859 | Start Date*: 2022-04-21 | ||||||||||||||||
Sponsor Name:Inselspital, Bern University Hospital | ||||||||||||||||||
Full Title: High Dose Steroids in Children with Stroke and Unilateral Focal Arteriopathy: A Multicentre Randomized Controlled Trial | ||||||||||||||||||
Medical condition: Focal cerebral arteriopathy and childhood stroke Focal cerebral arteriopathy (FCA) is an inflammatory vessel wall disease provoked by infection. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Trial now transitioned) DE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000178-20 | Sponsor Protocol Number: MCT8-2014-1 | Start Date*: 2015-08-12 |
Sponsor Name:Erasmus Medical Centre | ||
Full Title: Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. | ||
Medical condition: This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic ... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male | |
Trial protocol: BE (Completed) CZ (Completed) DE (Completed) IT (Completed) FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000192-33 | Sponsor Protocol Number: SB-913-1602 | Start Date*: 2018-08-17 | |||||||||||
Sponsor Name:Sangamo Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 1/2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects with Mucopolysaccharidosis II (MPS II) | |||||||||||||
Medical condition: Mucopolysaccharidosis type II (MPS II) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000206-28 | Sponsor Protocol Number: SB-318-1502 | Start Date*: 2018-08-14 | |||||||||||
Sponsor Name:Sangamo Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 1/2, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of SB-318, a rAAV2/6-based Gene Transfer in Subjects with Mucopolysaccharidosis I (MPS I) | |||||||||||||
Medical condition: Mucopolysaccharidosis type I (MPS I) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003180-54 | Sponsor Protocol Number: 20275 | Start Date*: 2020-04-25 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: An extension study to evaluate the long-term outcomes of subjects who received treatment for retinopathy of prematurity in Study 20090 | |||||||||||||
Medical condition: Retinopathy of prematurity | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Completed) AT (Prematurely Ended) HU (Completed) ES (Trial now transitioned) NL (Prematurely Ended) PT (Trial now transitioned) GR (Trial now transitioned) BE (Trial now transitioned) SK (Trial now transitioned) BG (Trial now transitioned) LV (Completed) EE (Completed) IT (Trial now transitioned) PL (Completed) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004909-27 | Sponsor Protocol Number: DNLI-E-0002 | Start Date*: 2020-07-22 | |||||||||||
Sponsor Name:Denali Therapeutics Inc. | |||||||||||||
Full Title: A PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DNL310 IN PEDIATRIC SUBJECTS WITH HUNTER SYNDROME | |||||||||||||
Medical condition: Hunter Syndrome (Mucopolysaccharidosis Type II [MPS II]) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002726-84 | Sponsor Protocol Number: SHP607-203 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Premacure AB | |||||||||||||
Full Title: Long-Term Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment with SHP607 in Extremely Premature Infants | |||||||||||||
Medical condition: Chronic Lung Disease | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006295-37 | Sponsor Protocol Number: 06/AN/04 | Start Date*: 2007-04-05 | |||||||||||
Sponsor Name:NHS Greater Glasgow & Clyde | |||||||||||||
Full Title: A multi-site RCT comparing regional and general anaesthesia for effects on neurodevelopmental outcome and apnoea in infants. | |||||||||||||
Medical condition: Inguinal hernia in neonates and infants | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002702-30 | Sponsor Protocol Number: ALXN1101-MCD-202 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Origin Biosciences, Inc. | |||||||||||||
Full Title: A PHASE 2/3, MULTICENTER, MULTINATIONAL, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALXN1101 IN NEONATES WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A | |||||||||||||
Medical condition: Molydenum CoFactor Deficiency (MoCD) Type A | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) IT (Prematurely Ended) NO (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
